NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005–09). Key growth drivers include growing use of chronic high-value innovative treatments driven by an aging population, high public healthcare expenditure as proportion of total healthcare expenditure, physician preference for prescribing branded drugs as well as high patient brand loyalty.
Features and benefits
* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in France
* Assesses the size of the French pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
* Examines the French generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Despite having a higher birth rate than most European countries, with its ageing populat